Aktis raises $318M in 2026’s first biotech IPO

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Radiopharmaceutical drug developer Aktis Oncology on Thursday said it raised $318 million from an initial public offering, the first for a biotechnology company in 2026. Aktis priced 17.65 million shares at $18 each, more than what it planned to sell, according to an updated securities filing earlier this week. It upsized the round after Eli Lilly, which previ ...